Stock Analiz

Cerus Corp. CERS

Medical/Dental Instruments · IPO 1997 · data as of November 13, 2026

$1.99Market cap $401M
Open the interactive analysis →

Cerus Corp. (CERS) is a healthcare company listed in the US with a market value of about $401M. In the twelve months to September 30, 2026 it had revenue of $254M and net income of -$7M, a net margin of -2.9%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 811.5, 5-year revenue growth of 15% a year, a 5-year average ROIC of -14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 96% below the current price.

About Cerus

Cerus is listed in the US and classified in medical/dental instruments, IPO year 1997. Revenue went from $36M in 2014 to $234M in 2025, growth of about 18.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 8% over three years (dilution for shareholders). It spends 29% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Positive free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E794.0
P/FCF811.5
P/S1.6
P/B5.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield0.1%
Shareholder yield0.0%
Intrinsic value vs. price−96%

Growth and quality

Revenue growth (1 yr)16.1%
Revenue growth (5 yrs, per year)15.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-18.8%
ROIC (5-yr avg.)-13.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$254M$234M$201M$187M$188M$160M$114M$94M$76M$51M$39M
Net income-$7M-$16M-$21M-$37M-$43M-$54M-$60M-$71M-$58M-$61M-$63M
Free cash flow$494000$1M$9M-$48M-$28M-$35M-$43M-$74M-$32M-$53M-$54M
EPS (diluted)$-0.03$-0.08$-0.11$-0.21$-0.24$-0.32$-0.37$-0.51$-0.44$-0.56$-0.62
Net margin-2.9%-6.7%-10.4%-20.1%-22.7%-34.1%-52.4%-76.0%-75.7%-118.0%-160.2%
ROIC—-4.2%-7.3%-16.0%-17.4%-24.5%-28.4%-44.9%-37.9%-65.9%-62.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $5.12, 158% above the current price; targets range from $4.00 to $6.50; the consensus rating is “Strong buy”; expected EPS is $-0.02 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Cerus stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 96% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Cerus pay a dividend?

Not currently.

Is Cerus a good stock to buy?

We do not give buy or sell advice. Cerus scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.